145 related articles for article (PubMed ID: 12600417)
21. Assessment of cytotoxicity of carbon nanoparticles using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability assay.
Schrand AM; Lin JB; Hussain SM
Methods Mol Biol; 2012; 906():395-402. PubMed ID: 22791451
[TBL] [Abstract][Full Text] [Related]
22. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
23. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
[TBL] [Abstract][Full Text] [Related]
24. The use of the MTT assay to study drug resistance in fresh tumour samples.
Sargent JM
Recent Results Cancer Res; 2003; 161():13-25. PubMed ID: 12528795
[TBL] [Abstract][Full Text] [Related]
25. [Chemosensitivity test for gastric cancer by in vitro MTT assay].
Ohyama S; Yonemura Y; Kinoshita K; Ninomiya I; Tugawa K; Kimura H; Miyazaki I; Tanaka M; Endo Y; Sasaki T
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1593-7. PubMed ID: 1908213
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Ling YH; Donato NJ; Perez-Soler R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
[TBL] [Abstract][Full Text] [Related]
27. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
[TBL] [Abstract][Full Text] [Related]
28. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
29. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
30. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
Kubota T; Egawa T; Otani Y; Furukawa T; Saikawa Y; Yoshida M; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2003; 23(1B):583-7. PubMed ID: 12680150
[TBL] [Abstract][Full Text] [Related]
31. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
[TBL] [Abstract][Full Text] [Related]
32. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Hightower RD; Sevin BU; Perras JP; Untch M; Angioli R; Ramos R; Averette H
Gynecol Oncol; 1992 Nov; 47(2):186-90. PubMed ID: 1468696
[TBL] [Abstract][Full Text] [Related]
33. New chemosensitivity test using a thermo-reversible gelation polymer for recurrent gynecologic cancer patients and a preliminary study of mechanisms of anticancer drug resistance.
Ohara T; Kiguchi K; Tsukikawa S; Sato S; Kobayashi Y; Ishizuka B; Kubota S
Hum Cell; 2005 Sep; 18(3):171-80. PubMed ID: 17022150
[TBL] [Abstract][Full Text] [Related]
34. Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Anticancer Drugs; 2003 Oct; 14(9):715-23. PubMed ID: 14551504
[TBL] [Abstract][Full Text] [Related]
35. [Resistance/sensitivity in vitro in ovarian cancer patients].
Sedláková I; Tosner J; Rezác A; Cervinka M; Brigulová K; Spacek J; Tomsová M; Skapinec P
Ceska Gynekol; 2010 May; 75(3):182-7. PubMed ID: 20731297
[TBL] [Abstract][Full Text] [Related]
36. Drug therapy for gynaecological cancer in older women.
van Rijswijk RE; Vermorken JB
Drugs Aging; 2000 Jul; 17(1):13-32. PubMed ID: 10933513
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
38. The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Nguyen HN; Sevin BU; Averette HE; Perras J; Donato D; Penalver M
Gynecol Oncol; 1992 May; 45(2):185-91. PubMed ID: 1592285
[TBL] [Abstract][Full Text] [Related]
39. Chemosensitivity testing predicts survival in ovarian cancer.
Taylor CG; Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Chappatte O; Hill JG
Eur J Gynaecol Oncol; 2001; 22(4):278-82. PubMed ID: 11695809
[TBL] [Abstract][Full Text] [Related]
40. Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay.
Lee SW; Kim YM; Kim MB; Kim DY; Kim JH; Nam JH; Kim YT
Tohoku J Exp Med; 2009 Dec; 219(4):277-82. PubMed ID: 19966525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
